Clinical Trials

Patients from 40 states & 3 countries

Our patients have traveled from around the world for our leading-edge programs, clinical trials, personalized treatment plans and quality of life and survivorship programs for both adult and pediatric brain tumor patients.

100+ physicians, researchers, scientists and staff

Our team at the Wells Center for Brain Tumor Therapy at UF includes experts in several specialties, including specialty surgical care, radiation therapy, laser ablation therapy, neuro-oncology care, genetic testing and precision medicine.

Over $10 million a year invested in research funding

From immunotherapy to chemotherapy, optune therapy and unique clinical trials, we are leading the country in searching for a cure for brain tumors.

Fast Facts

Our clinical trials portfolio includes:

  • More than 40 research studies
  • More than 10 Pediatric-focused studies
  • Five phase-1 Trials
  • First-In-Human treatments
  • Investigational New Drugs developed at UF

Listed below are the clinical trials that we are currently enrolling at UF, for general questions about clinical trials please contact John Lybarger at 

Featured Trial


Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ and MGMT-unmethylated Adult GBM

Subject Inclusion criteria:

  • Age: 18 years and older (Adult, Older Adult)
  • Newly-diagnosed de novo GBM based on the absence of the a previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (Secondary GBM not eligible)
  • The tumor must have a supratentorial component.
  • MGMT-unmethylated and CD70 positive (≥20%, 1+)

See full inclusion criteria and learn more about the IMPACT Clinical Trial (Link to the
Contact Phuong Deleyrolle to hear more about the IMPACT Clinical Trial   (

PNOC 020

A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).

Subject inclusion criteria:
  • Age: 21 Years and older (Adult, Older Adult)
  • Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
  • The tumor must have a supratentorial component.
  • Bone Marrow, Renal and Hepatic tests

See full inclusion criteria and learn more about the PNOC 020 Clinical Trial

Contact Marcia Hodik to hear more about the PNOC 020 Clinical Trial.


Browse or search current neurosurgery clinical trials


Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas


BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide

HeadStart 4

Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue


A Prospective, Multi-Center, Single Arm Study to obtain “real world” clinical data and characterize the acute and long-term performance of the MICRUSFRAME and GALAXY coils including the PulseRider Aneurysm Neck Reconstruction device for the endovascular treatment of intracranial aneurysms.


Pilot Study of Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the treatment of Newly Diagnosed Glioblastoma Patients


Assessment of Safety and Efficacy of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients with Probable Alzheimer's Disease

PNOC 019

A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)


A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma


A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with Glioblastoma Brain Tumors.


Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG).


Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults

PNOC 020

A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).


PNOC 021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas


Embolization of the Middle Meningeal Artery with ONYXTM Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma Evacuation